medEctoin® in
Airway Diseases
Discover the health benefits of medEctoin® products in allergic and non-allergic Asthma as well as acute bronchitis.
Validated Claims for Airway Health
Our medEctoin® Inhalation Solution has been shown to provide relief from respiratory symptoms, reduce airway inflammation, and promote recovery from environmental exposure to pollutants or allergens.
-
Effective Treatment for All Common Airway Diseases.
The potent inflammation-reducing properties of medEctoin® help soothe inflamed airways, reducing the irritation associated with chronic lung diseases such as asthma, COPD, and bronchitis.
-
Treatment and Prevention of Bronchitis Symptoms.
For supportive treatment and prevention of bronchitis symptoms. medEctoin® helps improve the clearance of mucus by keeping the airways moist and reducing irritation, which can facilitate more effective coughing and mucus expulsion.
-
Treatment and Prevention of Allergic and Non-Allergic Asthma Symptoms.
medEctoin® forms a protective barrier on the lining of the airways, shielding delicate respiratory tissues from irritants like pollutants, allergens, and smoke that can aggravate lung conditions.
-
Intense Moisturization of Upper and Lower Airways.
medEctoin® helps retain moisture in the mucous membranes of the respiratory system, preventing dryness and irritation that can exacerbate breathing difficulties, especially in conditions like chronic bronchitis.
-
Can be Used With All Common Nebulizers.
For administration with jet, mesh and ultrasound nebulizers (tested with e.g. Pari and Omron).
Clinically Proven:
medEctoin® in Airway Diseases
medEctoin® creams combat inflammatory skin conditions such as psoriasis and eczema. This is not just the testimony of consumers; scientists from around the world have been able to confirm numerous clinical effects in studies.
Siginificant Improvement of Bronchitis Symptoms
Participants
120 patients older than 5 years of age, who suffer from acute bronchitis and/or acute respiratory infections.
Duration
7 days.
Method
This study comprised an inclusion visit (day 1), a final visit (day 7), and a follow-up questionnaire (day 17).
Treatment
Patients applied the 2.5 ml inhalation solution two to four times a day,
with each application of 2.5 ml.
Ask an Expert
Prof. Dr. Ralph Mösges was the chairman of the International Standardization Committee for the Objective Assessment of the Upper Airways (ISCOANA), a task force of the International Rhinologic Society (IRS) and serves as a member of the guidelines committee of the German Academy of Otorhinolaryngology.
Success Stories
"bitop and Solinea already wrote great history with medEctoin® Inhalation but we believe that the future will be even more successful."
Solinea
Product Management
Join the Success Story of medEctoin®:
License Our Creams Under Your Brand
Your logo could soon be featured on these products – and all in just 8 months. Learn more about claims and applications by clicking on the product of your choice.
